Alignment Healthcare (ALHC) CEO John Kao sells 298K shares via 10b5-1 trust plan

Rhea-AI Filing Summary

Alignment Healthcare, Inc. insider John E. Kao, Chief Executive Officer and director, reported selling 298,000 shares of common stock on 2026-08-10 at a weighted-average price of $13.8818 per share, in multiple trades between $13.62 and $14.30. The sold shares are held indirectly through the JEK Trust, where Mr. Kao serves as trustee, leaving 790,766 common shares held indirectly after the sale. A separate entry shows 1,608,743 common shares held directly as of the same date. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 11/21/2025.

Insider Trade Summary 10b5-1

Net Seller: 298,000 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 298,000 shs ($4.14M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	298,000	$13.8818	$4.14M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 790,766 shares (Indirect, See Footnote); Common Stock — 1,608,743 shares (Direct)

Footnotes (3)

1. F1. Date of Rule 10b5-1 plan adoption: 11/21/2025
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.62 to $14.30. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Key Figures

Shares sold: 298,000 shares Weighted-average sale price: $13.8818 per share Sale price range: $13.62 to $14.30 per share +3 more

6 metrics

Shares sold 298,000 shares Common Stock sale on 2026-08-10

Weighted-average sale price $13.8818 per share 298,000-share sale on 2026-08-10

Sale price range $13.62 to $14.30 per share Multiple transactions included in reported sale

Indirect holdings after sale 790,766 shares Common Stock held indirectly via JEK Trust after 2026-08-10 sale

Direct holdings reported 1,608,743 shares Common Stock held directly as of 2026-08-10

Rule 10b5-1 plan adoption date 11/21/2025 Plan governing reported sale transactions

Key Terms

Rule 10b5-1 plan, weighted-average price, indirect, trustee

4 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 11/21/2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

indirect financial

"Represents securities held by JEK Trust ... of which Mr. Kao is the trustee."

trustee financial

"JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/10/2026 - 06:14 PM Accepted by SEC EDGAR 08/10/2026 - 06:14 PM Learn about SEC filing dates

FAQ

What insider transaction did Alignment Healthcare (ALHC) report for CEO John E. Kao?

Alignment Healthcare CEO John E. Kao reported a sale of 298,000 shares of common stock on 2026-08-10. The sale was executed at a weighted-average price of $13.8818 per share in multiple transactions.

At what prices did John E. Kao sell Alignment Healthcare (ALHC) shares on 2026-08-10?

The 298,000 ALHC shares sold by John E. Kao on 2026-08-10 were executed in multiple trades at prices ranging from $13.62 to $14.30 per share, with a weighted-average price of $13.8818.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after this Form 4 transaction?

After the reported sale, John E. Kao holds 790,766 ALHC shares indirectly through a trust and 1,608,743 shares directly. These figures represent his reported common stock positions following the 2026-08-10 transactions.

Were John E. Kao’s Alignment Healthcare (ALHC) share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on 11/21/2025. Such plans pre-arrange trade terms, which can reduce the timing significance of reported insider sales.

What is the ownership nature of the Alignment Healthcare (ALHC) shares sold by John E. Kao?

The 298,000 ALHC shares sold are held indirectly by the JEK Trust dated February 8, 2021, for which John E. Kao is trustee. The filing also reports a separate direct holding of 1,608,743 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CALIFORNIA 92868

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S(1)		298,000	D	$13.8818(2)	790,766	I	See Footnote(3)
Common Stock								1,608,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.62 to $14.30. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)